about
Insight into the Molecular Imaging of Alzheimer's DiseaseQuantitative detection of amyloid-β peptides by mass spectrometry: state of the art and clinical applicationsPlasma proteomic profiling in HIV-1 infected methamphetamine abusersChallenges for biomarker discovery in body fluids using SELDI-TOF-MS.Analysis of the mitochondrial proteome in multiple sclerosis cortex.Neuroproteomics as a promising tool in Parkinson's disease research.cNEUPRO: Novel Biomarkers for Neurodegenerative Diseases.Neuroproteomics: a biochemical means to discriminate the extent and modality of brain injury.Biomarkers of inflammation and amyloid-beta phagocytosis in patients at risk of Alzheimer disease.Protein markers for the differential diagnosis of vascular dementia and Alzheimer's disease.The "Alzheimer's disease signature": potential perspectives for novel biomarkers.Biomarker candidates of neurodegeneration in Parkinson's disease for the evaluation of disease-modifying therapeuticsBiomarkers for Alzheimer disease in cerebrospinal fluid, urine, and blood.Biomarkers for evaluation of clinical efficacy of multipotential neuroprotective drugs for Alzheimer's and Parkinson's diseases.Quantitative neuroproteomics: classical and novel tools for studying neural differentiation and function.Problems associated with fluid biomarkers for Parkinson's disease.Quantification of α-synuclein in cerebrospinal fluid as a biomarker candidate: review of the literature and considerations for future studies.Cerebrospinal fluid biomarkers for Alzheimer's disease: the present and the future.Intraneuronal β-amyloid and its interactions with proteins and subcellular organelles.Cerebrospinal fluid biomarker candidates for parkinsonian disorders.Biomarkers for prediction and targeted prevention of Alzheimer's and Parkinson's diseases: evaluation of drug clinical efficacy.A proteomics performance standard to support measurement quality in proteomics.Synaptic proteins in CSF as potential novel biomarkers for prognosis in prodromal Alzheimer's disease.Reduced penetrance of the PSEN1 H163Y autosomal dominant Alzheimer mutation: a 22-year follow-up study.
P2860
Q26765945-58DC6BDA-0DD4-4F44-8976-EACE131FC3A9Q26995267-A8D8A683-520A-4E51-9F55-6391C8EC2177Q28480898-A104DA2B-FFE1-4CD8-9E30-CEEBBC32845AQ33520447-7B3AEDDC-D07A-45CE-AA4B-4F441CB70CD1Q33812214-56DA6D8F-856D-4971-9B14-1D9DAFB4D375Q33821316-6342BD41-F8B3-470C-8133-6270D94CBF41Q34155662-2FD13C0B-C776-4D6F-8489-6AF9718A3436Q34193737-273FBCE1-2676-46D6-B918-016664EF2C55Q34201803-A9B8833D-D620-403B-8D37-2610B149091BQ34305901-88998764-13DB-4F98-82EB-74BEB6AAB754Q35339326-A249ACEA-90AF-46FB-808B-458C77D2A330Q35649302-6D4716DE-09BA-41F6-8453-12379D3BE6CBQ37273675-74A58FA2-BD6A-4049-BD2D-452FD10D120CQ37358672-B46049B5-DE4D-44EA-8B13-FCB043A1BF9AQ37721307-B47A637F-2E3D-43F6-A7E2-AC61718371D0Q37800100-2742E7EA-233D-4A2B-926D-96190A2A8A70Q37800101-3A241C3C-3C2E-455E-8328-93BE3052B027Q37895052-B2E6909A-9ED4-4964-A54D-38960439DCBCQ38060656-019B472C-EF4C-4189-AEEC-146DD7BCD5B6Q38076411-CB1363B1-F897-4660-AA48-8F295E1AB5DFQ42126269-1C3B39E4-F910-46E1-A224-D1B0E14B4A0EQ45166594-C0FFA08D-01C3-465B-9204-F88ACC1602D3Q47556392-EBAB3824-20AA-4BCB-AA5B-E5D9AD1FACD5Q55178076-F19C9464-E0F2-4F82-B1B0-BF5F6AE99441
P2860
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 13 February 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Clinical proteomics in neurodegenerative disorders.
@en
Clinical proteomics in neurodegenerative disorders.
@nl
type
label
Clinical proteomics in neurodegenerative disorders.
@en
Clinical proteomics in neurodegenerative disorders.
@nl
prefLabel
Clinical proteomics in neurodegenerative disorders.
@en
Clinical proteomics in neurodegenerative disorders.
@nl
P2860
P50
P1476
Clinical proteomics in neurodegenerative disorders.
@en
P2093
U Andreasson
U Rüetschi
P2860
P356
10.1111/J.1600-0404.2007.00985.X
P407
P577
2008-02-13T00:00:00Z